trans-alpha-Necrodyl acetate is a necrodane-type monoterpenoid strongly associated with Lavandula stoechas subsp. luisieri rather than mainstream lavender chemotypes. In the AromaForge archive it is most relevant as the dominant marker of the lavender-seville record, where it defines an unusual chemotype rich in necrodane derivatives. The public evidence is strongest for identity, occurrence, and mixture-level antimicrobial context; direct isolated-compound human safety or clinical literature remains sparse, so archive copy should frame it as a distinctive compositional marker with limited standalone pharmacology evidence.
Chemical identity and composition
NIST lists trans-alpha-necrodyl acetate as a stereochemically defined necrodane-related compound with formula C12H20O2. Current public chemistry references support the identity and stereochemical distinction from the cis isomer, but a reliable CAS registry number was not verified in this pass.
Aroma and practical use
- Use the recorded herbal, camphoraceous, lavender-like, green, herbaceous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2023 full-text study reported trans-alpha-necrodyl acetate at 40.2% in L. stoechas subsp. luisieri oil and found that this necrodane-rich oil showed stronger antimicrobial activity than the comparison Lavandula oil.
The paper ties the compound to the chemotype and reports MIC and MBC/MFC values for the whole essential oil, not the isolated constituent.
This experimental finding does not establish benefit, dose or safety in people using this blend.
The same 2023 study reported marked NHDF fibroblast cytotoxicity for the necrodane-rich luisieri oil, indicating that high-necrodane profiles need conservative topical framing.
Cell viability was reported around 30% across tested concentrations for the whole oil, so this is a mixture-level safety signal rather than a constituent-specific dermal limit.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A PubMed-indexed necrodane monoterpenoid paper linked L. luisieri oil and extract with activity against Candida albicans and several Gram-positive bacteria, but the accessible abstract does not isolate the contribution of trans-alpha-necrodyl acetate alone.
This supports bioactivity context for the chemotype while leaving constituent-level attribution unresolved.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Screening assumption (family fallback). It is not a verified constituent-specific exposure limit.
model fallback · Tisserand Institute — Essential Oil Safety Maximum Dermal Use Level guidance (general oxygenated monoterpenoid constituents e.g. linalool, geraniol, linalyl acetate)No constituent-specific IFRA limit, RIFM dossier, or standalone human toxicology package for trans-alpha-necrodyl acetate was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
The most concrete safety signal located here is mixture-level cytotoxicity from necrodane-rich L. luisieri oil rather than direct testing of isolated trans-alpha-necrodyl acetate.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
Because evidence is sparse and the parent oil showed fibroblast toxicity in vitro, any consumer-facing summary should stay conservative and avoid topical-benefit claims.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
association_with_necrodane_rich_antifungal_profiles
MDPI's luisieri oil study links higher necrodane-content chemotypes, including trans-alpha-necrodyl acetate, with stronger antifungal activity at the whole-oil level.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
defensive_or_ecological_necrodane_scaffold
Necrodane derivatives were originally identified in defensive beetle secretions, supporting an ecological-defense interpretation of the scaffold rather than a human therapeutic mechanism.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- No verified CAS registry number was confirmed from the sources used in this pass.
- Direct isolated-compound pharmacology for trans-alpha-necrodyl acetate is much thinner than the whole-oil literature.
- No dedicated constituent-specific dermal safety assessment was located.
- Second pass (2026-07-13): searched for IFRA/RIFM data for necrodyl-acetate necrodane compounds specific to Lavandula stoechas subsp. luisieri; confirmed via multiple sources that no CAS-specific fragrance safety assessment exists for these niche necrodane monoterpenoids. The prior dermal_limit_pct 20 had no traceable citation and is corrected to null pending real data.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.